Find out about the latest clinical trials for cancer patients,
including novel immunotherapy approaches.

APRIL 2017
Providence Cancer Center is currently conducting more than 160 research studies, including trials of targeted therapies and novel immunotherapy approaches. Please see the links below for a list of studies in specific disease areas.
Highlight: Immunotherapy Studies for  Hematologic Malignancies
Dev eloping new immunotherapies for blood-related cancers is the primary  research focus of the Hematologic Malignancies Program at Providence Cancer Center. 

John Godwin, M.D., who heads up the program, is a nationally known expert in leukemia and lymphoma and a member of the National Cancer Institute's Leukemia Steering Committee. He is actively involved in both research and patient care at Providence. Under his leadership, our multidisciplinary team offers patient-focused care, expert second opinions for complex cases, and cutting-edge research studies of the most promising agents. Many of our clinical trials are first-in-human studies of new immunotherapies aimed at maximizing the potential of the immune system to destroy tumors. 

Currently, 20 clinical trials - of which most are immunotherapy studies - are open to patients with hematologic cancers. Here are five of them:
All current open studies:
New studies are posted frequently - please check our  website   for a complete list of our current studies. For more information, call 503-215-2614.